Live Breaking News & Updates on Metastatic Lung Cancer

Stay updated with breaking news from Metastatic lung cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Uncertainty Surrounds Sensitivity of ctDNA in CRC

CtDNA is a useful prognostic tool in CRC, but it's unclear whether it can guide the use of adjuvant chemotherapy. ....

United States , Memorial Sloan Kettering Cancer Center , New York , David Ellison , Aparna Raj Parikh , Hiroki Yukami , Eujung Kim , Harvard Medical School , Peter Maccallum Cancer Centre , Pashtoon Murtaza Kasi , Weill Cornell Medicine , Jeannie Tie , Raj Parikh , Not Sensitive , Colorectal Cancer , Colorectal Cancer Crc , Adjuvant Chemotherapy , Hepatocellular Carcinoma Hcc Liver Cancer Of The , Secondary Malignant Neoplasm Of The Lung , Econdary Malignant Lung Neoplasm , Secondary Lung Cancer , Metastatic Lung Cancer , Ung Metastases , Lung Metastasis ,

Future Perspectives in KRAS G12C-Mutated NSCLC

In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape. ....

Exploring Hepatotoxicity , Treatment Outcomes , Lung Cancer , Non Small Cell Lung Cancer , Metastatic Lung Cancer , Metastatic Nsclc , Metastatic Non Small Cell Lung Cancer ,

KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors. ....

Exploring Hepatotoxicity , Treatment Outcomes , Adverse Events , Lung Cancer , Non Small Cell Lung Cancer , Metastatic Lung Cancer , Metastatic Nsclc , Metastatic Non Small Cell Lung Cancer ,

Disease Progression Beyond Frontline KRAS G12C Inhibitors

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations. ....

Exploring Hepatotoxicity , Treatment Outcomes , Lung Cancer , Non Small Cell Lung Cancer , Metastatic Lung Cancer , Metastatic Nsclc , Metastatic Non Small Cell Lung Cancer ,

Advancements in Targeted Therapy for Metastatic NSCLC

Shared insight into the transformative impact of targeted therapies in lung cancer treatment, from adjuvant therapy breakthroughs to emerging trials, emphasizing the critical role of comprehensive molecular testing. ....

Precision Oncology , Molecular Genotyping , Optimal Treatment , Metastatic Nonsquamous , Targeted Therapy , Non Small Cell Lung Cancer , Metastatic Nsclc , Metastatic Non Small Cell Lung Cancer , Molecular Testing , Egfr Mutations , Targeted Therapy Advancements , Advancements In Targeted Therapy , Metastatic Lung Cancer , Kras G12c Inhibitors ,